Abbott Laboratories (ABT)

Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.

Pulsed field ablation and expanded cancer screening tools position the core business for accelerated growth beyond historical rates.

Abbott plans nutrition spinoff by end of 2027 amid strong Q3 growth.

Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent publicly traded company through a tax-free distribution to shareholders. Chairman and Chief Executive

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $...

It was Griffin's biggest add for Citadel last quarter.

These companies pay durable and growing dividends.

Rising rates can expose dividend traps, but this Dividend King is built to keep paying.

The market's warning signs are driving me to shift my portfolio towards high-quality holdings.

These companies have a long history of dividend growth.

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.

A super-high yield isn't everything.

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

Abbott has a low-risk profile with significant upside potential.

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.

It's as stable and consistent as you'd hope from a dividend ETF.

It would be hard for investors to replicate the company's return over the past decade.